Research on improving treatments for childhood leukemia
Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact. Precision Medicine for Childhood Leukemia.
Chinese University of Hong Kong · NCT04478006
This study is testing new ways to treat childhood leukemia by looking at kids' genes to find better medicines and creating new treatments for those with tough cases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hong Kong, Hksar) |
| Trial ID | NCT04478006 on ClinicalTrials.gov |
What this trial studies
This study investigates the genomics and drug sensitivity of childhood leukemia to enhance precision medicine approaches. It consists of two main projects: the first focuses on sequencing genetic material from children with various types of leukemia to identify potential targeted therapies, while the second aims to develop novel antibodies for treating high-risk cases using animal models. The goal is to tailor treatments based on individual patient profiles and improve outcomes for those with relapsed or refractory leukemia.
Who should consider this trial
Good fit: Ideal candidates include children diagnosed with acute lymphoblastic leukemia, acute myeloid leukemia, mixed phenotype acute leukemia, juvenile myelomonocytic leukemia, or myelodysplastic syndromes.
Not a fit: Patients who are unable to understand English or Chinese, or those who refuse participation, will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer targeted therapies for children with high-risk leukemia.
How similar studies have performed: Other studies have shown promise in using genomics and targeted therapies for childhood leukemia, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
List of inclusion criteria: 1. acute lymphoblastic leukemia (ALL) or 2. acute myeloid leukemia (AML) or 3 .mixed phenotype acute leukemia (MPAL) or 4\. juvenile myelomonocytic leukemia (JMML) or 5\. myelodysplastic syndromes (MDS) or 6\. normal bone marrow donor List of exclusion criteria: 1. This study will not recruit subjects who are unable to understand English or Chinese. 2. Patient or parent refusal
Where this trial is running
Hong Kong, Hksar
- Hong Kong Children Hospital — Hong Kong, Hksar, China (RECRUITING)
Study contacts
- Principal investigator: Kam Tong Leung, Ph. D. — Chinese University of Hong Kong
- Study coordinator: Kathy Chan, Ph. D.
- Email: kathyyychan@cuhk.edu.hk
- Phone: 852-35052858
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Childhood Leukemia